July 7, 2019  |  

Cancer genomics: technology, discovery, and translation.

Authors: Tran, Ben and Dancey, Janet E and Kamel-Reid, Suzanne and McPherson, John D and Bedard, Philippe L and Brown, Andrew M K and Zhang, Tong and Shaw, Patricia and Onetto, Nicole and Stein, Lincoln and Hudson, Thomas J and Neel, Benjamin G and Siu, Lillian L

In recent years, the increasing awareness that somatic mutations and other genetic aberrations drive human malignancies has led us within reach of personalized cancer medicine (PCM). The implementation of PCM is based on the following premises: genetic aberrations exist in human malignancies; a subset of these aberrations drive oncogenesis and tumor biology; these aberrations are actionable (defined as having the potential to affect management recommendations based on diagnostic, prognostic, and/or predictive implications); and there are highly specific anticancer agents available that effectively modulate these targets. This article highlights the technology underlying cancer genomics and examines the early results of genome sequencing and the challenges met in the discovery of new genetic aberrations. Finally, drawing from experiences gained in a feasibility study of somatic mutation genotyping and targeted exome sequencing led by Princess Margaret Hospital-University Health Network and the Ontario Institute for Cancer Research, the processes, challenges, and issues involved in the translation of cancer genomics to the clinic are discussed.

Journal: Journal of clinical oncology
DOI: 10.1200/JCO.2011.39.2316
Year: 2012

Read publication

Talk with an expert

If you have a question, need to check the status of an order, or are interested in purchasing an instrument, we're here to help.